Posted by Michael Wonder on 11 Sep 2023
Verona Pharma announces the US FDA has accepted the new drug application filing for ensifentrine for the maintenance treatment of COPD
11 September 2023 - PDUFA target action date of 26 June 2024.
Verona Pharma announces the US FDA has accepted for review the Company’s new drug application seeking approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.
